John Libbey Eurotext

European Journal of Dermatology

MENU

Serum salusin-α and salusin-β levels in patients with Behcet's disease Volume 24, numéro 5, September-October 2014

Illustrations

  • Figure 1

Tableaux

Auteurs
1 Elazig Education and Research Hospital Department of Dermatology, Elazig, Turkey
2 Firat University Faculty of Medicine Department of Dermatology, Elazig, Turkey
3 Dicle University Medicine Faculty Department of Dermatology, TR21070, Diyarbakir, Turkey
4 Firat University Faculty of Medicine, Department of Medical Biochemistry and Clinical Biochemistry (Firat Hormones Research Group)
* Reprints

Background: Behcet's disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients. Objective: The aim of this study was to determine serum salusin-α and salusin-β levels in BD patients and healthy controls and to investigate their association with MetS. Patients and Methods: Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-α and salusin-β levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS. Results: The mean serum salusin-α level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-β level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-α level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04). Conclusions:Serum salusin-α level (an anti-atherogenic molecule) was lower, while serum salusin-β level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-α and the increase in salusin-β levels contribute to the development of MetS.